German Biotech launches Phase II in a hot Target for Inflammation

09/06/2016 - 3 minutes

InflaRx has treated the first patient in a new Phase II trial, which is studying the potential of its anti-complement antibody in avoiding immunological complications after complex cardiac surgery – a big unmet need. It is competing with world most expensive drug Soliris from Alexion (US).

inflarx_c5a_complement_system_cardiac_surgeryBased in Jena (Germany), InflaRx specializes in developing new drugs to control inflammation. In order to do this, it targets the complement system – small proteins or peptides that stimulate the action of antibodies and immune cells.

Its lead candidate is IFX-1, a first-in class monoclonal antibody that binds to a particularly sought-after target of the complement system – C5a. This protein fragment is a key amplifier of inflammatory response.

InflaRx is applying its IFX-1 in a particular area of high unmet needs – complex cardiac surgery. In this kind of open-heart procedures, the patient is connected to a heart-lung-machine and the blood contacts with artificial surfaces – which can cause systemic, life-threatening inflammation.

The Phase II trial for this application has now been initiated,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member